Great Bay Bio is fundamentally an AI company for CDMO applications. Their technologies to mitigate pain points like high failure rates, long development timelines, and high costs in the biopharma industry. GBB has brought several biologic products to the NDA stage and continues to use its centralized database to develop an all-encompassing AI-enabled bioprocessing ecosystem. Their AI was most notably able to reduce a major MNC's cell line development time from 7 months down to 3 weeks, and that at a better yield, efficacy, and purity than all current methods.